- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03632213
Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI
A Randomized Clinical Trial to Evaluate the Effects of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mucopolysaccharidoses (MPS) are a group of lysosomal diseases characterized by deficiency of enzymes responsible for the degradation of glycosaminoglycans. MPS are multisystemic diseases with significant clinical overlap between their types, with cardiac problems being among the most commonly observed manifestations and are also among the main causes of mortality in these patients. Enzyme replacement therapy and bone marrow transplantation, despite being well established treatments, are not yet capable of reversing or preventing the progression of some of the cardiological manifestations of MPS. On the other hand, these patients may benefit from other conventional drug or surgical treatment, which can be instituted at an appropriate time if there is a better understanding of how these manifestations progress. In particular, the occurrence of aortic root dilation, although described in animal models, has only recently been evaluated in the studies on mucopolysaccharidoses.
In addition, verifying the effectiveness of losartan in controlling these manifestations in the animal model opens the perspective of clinical use of this drug. Losartan is a low-cost drug and, if its efficacy is demonstrated, may represent an accessible therapy directed at the unmet needs of these patients.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Diane Pedrini, RN
- Phone Number: +555133596340
- Email: dpedrini@hcpa.edu.br
Study Contact Backup
- Name: Fabiano Poswar, MD
- Phone Number: +555133596340
- Email: fposwar@hcpa.edu.br
Study Locations
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903
- Hospital de Clinicas de Porto Alegre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed biochemical or molecular diagnosis of MPS VI or MPS IVA.
- Age between 10 and 40 years.
- Presence of aortic root diameter greater than 1.0 standard deviation, as determined by local measurement.
- Be in a stable treatment regime in the last 3 months (without performing Enzyme replacement therapy (ERT), or performing ERT on a regular basis).
- Patient who agree to participate in the study protocol by signing a free informed consent form.
Exclusion Criteria:
- Patient who underwent previous aortic surgery.
- Patient with aortic root diameter greater than 5 cm.
- Patient on angiotensin-converting-enzyme (ACE) inhibitor. In case of use of beta-blocker, or calcium channel blocker, patient without adequate control of blood pressure in the last 3 months.
- Patients with previous adverse events related to treatment with losartan or contraindication to this treatment.
- Inability, in the opinion of the investigator, to complete the study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Losartan
Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
|
Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
|
Placebo Comparator: Placebo
Placebo group:15 patients, both sexes, will receive oral placebo for 12 months.
|
Placebo group: 15 patients, both sexes, will receive oral placebo for 12 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events related to losartan use
Time Frame: 12 months
|
The frequency of adverse events after 12 months will be compared among the groups
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Z score of maximal aortic root diameter measured by Valsalva sinus
Time Frame: 12 months
|
Reduction over time in the Z score of maximal aortic root diameter measured by Valsalva sinus echocardiogram between the baseline assessment and 12 months after treatment with losartan.
|
12 months
|
Changes of serum levels of transforming growth factor (TGF-Beta-1)
Time Frame: 12 months
|
Changes of serum levels of transforming growth factor (TGF-Beta-1) between baseline and 12 months
|
12 months
|
Changes of serum levels of brain-type natriuretic peptide (BNP)
Time Frame: 12 months
|
Changes of serum levels of brain-type natriuretic peptide between baseline and 12 months
|
12 months
|
Changes of serum levels of N-terminal pro b-type natriuretic peptide (NT-ProBNP)
Time Frame: 12 months
|
Changes of serum levels of N-terminal pro b-type natriuretic (NT-ProBNP) peptide between baseline and 12 months
|
12 months
|
Changes of serum levels of creatine kinase-myocardial ban (ck-mb)
Time Frame: 12 months
|
Changes of serum levels of creatine kinase-myocardial ban (ck-mb) between baseline and 12 months
|
12 months
|
Changes of serum levels of Chemokine (C-X-C motif) ligand 6 (CXCL6)
Time Frame: 12 months
|
Changes of serum levels of Chemokine (C-X-C motif) ligand 6 (CXCL6) between baseline and 12 months
|
12 months
|
Changes of serum levels of Chemokine (C-X-C motif) ligand 16 (CXCL16)
Time Frame: 12 months
|
Changes of serum levels of Chemokine (C-X-C motif) ligand 16 (CXCL16) between baseline and 12 months
|
12 months
|
Changes of serum levels of Endocan-1 (ESM-1)
Time Frame: 12 months
|
Changes of serum levels of Endocan-1 (ESM-1) between baseline and 12 months
|
12 months
|
Changes of serum levels of Placental growth factor (PLGF)
Time Frame: 12 months
|
Changes of serum levels ofPlacental growth factor (PLGF) between baseline and 12 months
|
12 months
|
Changes of serum levels of Fatty acid binding protein 3 (FAPB3)
Time Frame: 12 months
|
Changes of serum levels of Fatty acid binding protein 3 (FAPB3) between baseline and 12 months
|
12 months
|
Changes of serum levels of Fatty acid binding protein 4 (FAPB4)
Time Frame: 12 months
|
Changes of serum levels of Fatty acid binding protein 4 (FAPB4) between baseline and 12 months
|
12 months
|
Changes of serum levels of Oncostatin M
Time Frame: 12 months
|
Changes of serum levels of Oncostatin M between baseline and 12 months
|
12 months
|
Changes of serum levels of Troponin I
Time Frame: 12 months
|
Changes of serum levels of Troponin I between baseline and 12 months
|
12 months
|
Changes of ventricular-vascular coupling measures as assessed by echocardiography between the baseline and 12 months.
Time Frame: 12 months
|
Reduction over time in the ventricular-vascular coupling measures as assessed by echocardiography between the baseline and 12 months.
|
12 months
|
Changes in mitral valve regurgitation
Time Frame: 12 months
|
Alteration of the parameter of mitral valve regurgitation as assessed by a semi-quantitative echocardiographic method between the baseline and 12 months.
|
12 months
|
Changes in aortic valve regurgitation
Time Frame: 12 months
|
Alteration of the parameter of aortic valve regurgitation as assessed by a semi-quantitative echocardiographic method between the baseline and 12 months.
|
12 months
|
Changes in ejection fraction
Time Frame: 12 months
|
Alteration of the ejection fraction measurement as assessed by echocardiography between the baseline and 12 months.
|
12 months
|
Changes in left ventricular longitudinal strain
Time Frame: 12 months
|
Alteration of the measurement of left ventricular longitudinal strain as assessed by echocardiography between the baseline and 12 months.
|
12 months
|
Changes in E/A ratio
Time Frame: 12 months
|
Alteration of the parameter E/A ratio as assessed by echocardiography between the baseline and 12 months .
|
12 months
|
Changes in E/e' ratio
Time Frame: 12 months
|
Alteration of the parameter E/e' ratio as assessed by echocardiography between the baseline and 12 months.
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycosaminoglycan after 6 months
Time Frame: 6 months
|
Difference in urinary glycosaminoglycan levels after 6 months
|
6 months
|
Glycosaminoglycan after 12 months
Time Frame: 12 months
|
Difference in urinary glycosaminoglycan levels after 12 months
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Roberto Giugliani, MD, PhD, Hospital de Clinicas de Porto Alegre
- Study Director: Guilherme Baldo, PhD, Hospital de Clinicas de Porto Algre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Disease
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Bone Diseases
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Mucinoses
- Bone Diseases, Developmental
- Cardiovascular Diseases
- Syndrome
- Mucopolysaccharidoses
- Osteochondrodysplasias
- Mucopolysaccharidosis IV
- Mucopolysaccharidosis VI
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Losartan
Other Study ID Numbers
- 17-0685
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mucopolysaccharidoses
-
Assiut UniversityUnknown
-
Tehran University of Medical SciencesUnknownMucopolysaccharidosisIran, Islamic Republic of
-
Manchester University NHS Foundation TrustOrchard TherapeuticsRecruitingMucopolysaccharidosesUnited Kingdom
-
Hacettepe UniversityCompletedMucopolysaccharidosesTurkey
-
Mackay Memorial HospitalBioMarin PharmaceuticalUnknown
-
Shrouk Shaban BakrRecruiting
-
JCR Pharmaceuticals Co., Ltd.Active, not recruitingMucopolysaccharidosis IUnited States, Brazil, Japan
-
Lundquist Institute for Biomedical Innovation at...Swedish Orphan Biovitrum; Cure Sanfilippo FoundationCompleted
-
Genzyme, a Sanofi CompanyCompleted
-
JCR Pharmaceuticals Co., Ltd.CompletedMucopolysaccharidosis IUnited States, Brazil, Japan
Clinical Trials on Losartan
-
Baker Heart and Diabetes InstituteWithdrawn
-
National Institute of Diabetes and Digestive and...Johns Hopkins UniversityTerminatedNAFLD - Nonalcoholic Fatty Liver DiseaseUnited States
-
Chinese PLA General HospitalTianjin TongRenTang Group Co., Ltd.UnknownProteinuria | GlomerulonephritisChina
-
University of South FloridaNational Cancer Institute (NCI)CompletedPrecancerous ConditionUnited States
-
Organon and CoTerminated
-
Dong Wha Pharmaceutical Co. Ltd.Completed
-
Vifor PharmaCompleted
-
EMSSuspended
-
Steadman Philippon Research InstituteRecruitingKnee Arthroplasty, TotalUnited States